Alterity Therapeutics (PRNAD) Accounts Payables (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Accounts Payables for 16 consecutive years, with $1.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accounts Payables fell 21.85% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 21.85% YoY), while the FY2025 annual figure was $1.6 million, down 45.83% from the prior year.
• Accounts Payables came in at $1.0 million for Q4 2025 at Alterity Therapeutics, down from $1.6 million in the prior quarter.
• The five-year high for Accounts Payables was $3.6 million in Q2 2022, with the low at $35177.1 in Q2 2023.
• Average Accounts Payables over 5 years is $1.7 million, with a median of $1.8 million recorded in 2021.
• Across the five-year window, Accounts Payables jumped 8612.49% in 2021 and tumbled 99.03% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $2.3 million in 2021, then advanced by 27.9% to $2.9 million in 2022, then decreased by 19.05% to $2.4 million in 2023, then tumbled by 43.27% to $1.3 million in 2024, then retreated by 21.85% to $1.0 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $1.0 million, $1.6 million, and $1.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.